AGENUS going back in

Agenus AGEN is a stock that I have not followed since they were forced (unfairly) by the FDA to pull their NDA for balstilimab. However recently price action has started to look favourable and this is in conjuction with ASCO where the company is presenting clinical data from 2 trials.